Science author instructions page. These studies are important for a number of reasons. First, they used a gene therapy strategy that is feasible in the clinical setting. Second, they targeted and compared therapeutic strategies aimed at both the structural and metabolic defects associated with the dystrophic heart. Third, they utilized both the whole animal (mdx mouse) and an in vitro working heart model (i.e., the Langendorff heart preparation)
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to examine the impact of RNR or microdystrophin on the dystrophic heart function of the mdx mouse.
Fourth, the authors examined the impact of RNR or microdystrophin under baseline conditions and after stimulation (i.e., a pacing protocol). Collectively, these studies provide new insights regarding systolic (heart failure with reduced ejection fraction) and diastolic (heart failure with preserved ejection fraction) dysfunction in the dystrophic heart, and they provide a platform for future studies.
Additional studies will be necessary to examine the impact of combined therapies such as the combination of both RNR and microdystrophin (together) on the dystrophic heart. It will also be important to explore the effect of the dystrophic mdx heart E-mail: garry@umn.edu.
